Melanoma is one of the most aggressive tumors and, from the first moments, it can lead to fetastasis, which also occurs in an apparently disorganized way with the involvement of many processes. Now, a group of Spanish researchers have managed to find an order for this disorder.
In particular, scientists from the Melanoma Group for the National Center for Oncological Research (CNIO), led by Marisol Soengas, and in collaboration with Ysbyty Madrid on October 12, have shown that metastatic processes do not occur through "independent markets". , but they are coordinated by a general captain: the protein p62 ".
That is, a number of processes involving metastasis melanoma, which are so far considered independently of each other, have a global coordinator of the p62 protein above.
According to this work, one of the proteins controlled by p62 is FERMT2, explains a statement to the CNIO press, where it remembers that this had not already been associated with metastasis in melanoma.
The work shows that FERMT2 and p62 could be a prognostic indication of the evolution of the disease in patients.
These important findings from the Cancer Cell magazine were chosen to star in the scope of the January 2019 issue, according to the CNIO.
In order to reach their conclusions, the scientists conducted a full study with the most advanced biotechnology technologies and achieved a detailed feature of b62 and all the processes that are related to melanoma.
They analyze the expression of the genes associated with these processes -transgrifomic-, the structure and function of the proteins -proteome- and the interactions that occur between them -interactomic-.
From this analysis, this "new and unexpected" function of p62 has been stopped: managing the half-life of other proteins that are related to metastasis melanoma.
In addition, the scientists were trying to find out what other factors regulated by b62 which could also affect survival of patients.
Therefore, they identify a new protein, FERMT2, which corresponds to poorer prognosis of metastatic melanomas.
"For us, the pathologists, it was interesting to see that p62 and FERMT2 were increased in samples of patients with metastasis melanoma, because so far we do not have good tumor sequence marks," summed up José Luis Rodríguez-Peralto, Head A Pathological Anatomy Service from the 12th of October Hospital and co-author of this work.
In the next steps, the scientists will try, among others, to verify the results in a greater number of populations.